Pharmacy Benefit Manager
FTC report on pharmacy benefit managers uncovers a system ‘addicted to higher list prices’
The “big three” pharmacy benefit managers have imposed markups ranging from 100% to more than 7,000% on generic specialty drugs dispensed at their affiliated pharmacies, according to a Federal Trade Commission report released this year.
FTC files administrative complaint vs. PBMs alleging artificially inflated insulin prices
The Federal Trade Commission announced it has filed an administrative complaint against three pharmacy benefit managers alleging “anticompetitive and unfair” rebate practices that have artificially inflated the price of insulin drugs.
Rheum for Debate: Have biosimilars reduced drug costs for patients?
Welcome to the first-ever Healio Rheum for Debate, in which we ask experts to take opposing sides and match wits on major topics in the field of rheumatology.
Mark Cuban’s Cost Plus Drug Company ‘flying under the radar’ after 2 years
The Mark Cuban Cost Plus Drug Company launched in January 2022 to a flurry of promises, curiosity, and a certain guarded optimism among experts regarding its potential to lower medication prices for patients.
CVS Caremark to replace Humira with biosimilars on national commercial formularies
CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.
Adalimumab biosimilar ‘costs more than double’ Humira’s launch price despite discount
Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.
Cigna Pharmacy to list adalimumab biosimilars at same price point as originator
Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level as the originator Humira on its commercial formularies, according to a company press release.
AMA report finds significant collective market shares among top pharmacy benefit managers
Across the U.S., there is a lack of competition in local markets where pharmacy benefit managers work with commercial health insurers, an AMA analysis found.
Predatory copay practices, workforce shortage top legislative priorities for rheumatology
Addressing predatory copay schemes, the influence of pharmacy benefit managers and the ongoing rheumatology workforce shortage are currently among the top legislative priorities for officials at the American College of Rheumatology.
Nearly half of formulary exclusions offer ’questionable‘ clinical, economic benefit
Some formulary exclusions force patients to pay more for preferred drugs and use medications with dubious benefits for their needs, according to data published in the Health Science Journal.